Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NYKD.OL
- Price
- 2.03
- Stock movement down
- -0.11 (-5.05%)
- Company name
- Nykode Therapeutics ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 662.89M
- Ent værdi
- 554.15M
- Pris/omsætning
- 107.84
- Pris/bog
- 4.36
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- 33.92%
- 1 års afkast
- -85.70%
- 3 års afkast
- -63.77%
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2025-04-05
UDBYTTE
NYKD.OL betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 107.84 |
| Pris til egenkapital | 4.36 |
| EV i forhold til salg | 90.15 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 326.55M |
| EPS (TTM) | -0.12 |
| FCF pr. aktie (TTM) | -0.27 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 6.15M |
| Bruttofortjeneste (TTM) | 0.00 |
| Driftsindkomst (TTM) | -58.85M |
| Nettoindkomst (TTM) | -37.91M |
| EPS (TTM) | -0.12 |
| EPS (1 år frem) | -1.40 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | -957.39% |
| Fortjenstmargin (TTM) | -616.79% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 136.53M |
| Nettotilgodehavender | 0.00 |
| Omsætningsaktiver i alt | 140.02M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 9.28M |
| Sum aktiver | 179.88M |
| Kreditor | 3.42M |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 15.09M |
| Sum gæld | 27.80M |
| Aktionærernes egenkapital | 152.08M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -87.37M |
| Investeringsudgifter (TTM) | 1.09M |
| Fri pengestrøm (TTM) | -88.45M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -24.93% |
| Afkast af aktiver | -21.08% |
| Afkast af investeret kapital | -24.93% |
| Kontant afkast af investeret kapital | -58.16% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 2.17 |
| Daglig høj | 2.20 |
| Daglig lav | 2.01 |
| Daglig volumen | 2.35M |
| Højeste gennem alle tider | 83.20 |
| 1 års analytiker estimat | 11.50 |
| Beta | 1.31 |
| EPS (TTM) | -0.12 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 16 May 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| NYKD.OL | S&P500 | |
| Nuværende prisfald fra top notering | -97.56% | -17.56% |
| Højeste prisfald | -97.66% | -56.47% |
| Højeste efterår dato | 11 Mar 2025 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -71.72% | -11.07% |
| Gennemsnitlig tid til nyt højdepunkt | 119 days | 12 days |
| Maks. tid til nyt højdepunkt | 826 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
662.89M
Markedsværdi kategori
Small-cap
Beskrivelse
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Personale
179
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Norway
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
The European markets recently experienced a downturn, with the pan-European STOXX Europe 600 Index closing about 1.4% lower due to new U.S. trade tariffs impacting investor sentiment. Despite these ch...
3. april 2025
As global markets grapple with geopolitical tensions and consumer spending concerns, investors are keeping a close eye on economic indicators and policy shifts. Amidst this backdrop, the allure of pen...
25. februar 2025
With global markets experiencing volatility amid cautious Federal Reserve commentary and political uncertainty, investors are closely monitoring opportunities that can offer potential value. In this c...
27. december 2024
As global markets navigate the implications of the incoming Trump administration, investors are closely watching sectors influenced by potential policy shifts. In this context, penny stocks—typically ...
19. november 2024
OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
6. november 2024
OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
14. august 2024
OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
20. juni 2024
OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
11. juni 2024
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, toda...
14. maj 2024
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, toda...
14. maj 2024
Næste side